How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
As the European Parliament enters a new phase of transport law-making, the implementation of the Green Deal has become the central test for EU road-decarbonisation policy. Among the lawmakers shaping ...
DNA Ginkgo Bioworks Holdings, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback